The Lancet publication provides independent peer-reviewed validation of the BOND-003 data, which may increase the probability of FDA approval for cretostimogene in BCG-unresponsive NMIBC. Traders should monitor for the FDA decision date and any pre-submission meeting outcomes; a positive approval would be transformative for this single-asset company with a $6.1B market cap.
Drug in focus
CGON drug pipeline →cretostimogene
▲ Bullish Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- BLA submission planned for Q4 2026 in BCG-unresponsive NMIBC. If accepted and approved under standard FDA review, potential approval could come in H2 2027. The drug already has Breakthrough Therapy designation from the FDA.
- Next catalyst
- None dated
What to watchWatch for BLA submission completion in Q4 2026, this is the key catalyst that will determine whether cretostimogene becomes the first FDA-approved oncolytic virus therapy for NMIBC. Also monitor PIVOT-006 Phase 3 topline data (intermediate-risk NMIBC), which could be imminent. The $1.05B ATM facility creates ongoing dilution overhang, so positive regulatory catalysts are needed to offset that pressure.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 28 $72.62entry
- T+1 · 4mo ago −4.82%α −3.28% · $69.12
- T+5 · 4mo ago −4.78%α −7.05% · $69.15
- T+20 · 3mo ago +8.72%α +5.34% · $78.95
- T+60 · 27d ago −14.29%α −18.64% · $62.24
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CG Oncology published Phase 3 BOND-003 Cohort C results for cretostimogene in BCG-unresponsive NMIBC in The Lancet Oncology, showing a 75.5% complete response rate, median duration of response of 27.9 months, and no Grade 3+ treatment-related adverse events. The publication validates the clinical data ahead of a potential FDA decision, reinforcing the drug's profile as a potential bladder-sparing therapy in a high-need setting with no approved standard of care alternatives beyond cystectomy.
Key Facts
- Phase 3 BOND-003 Cohort C met its primary endpoint with statistical significance; 75.5% of patients achieved complete response at any time.
- Median duration of response was at least 27.9 months and is ongoing; 64.2% and 60.1% maintained response at 12 and 24 months, respectively.
- No Grade 3 or greater treatment-related adverse events, treatment-related discontinuations, or deaths reported.
- 96.6% of patients were free from progression to muscle-invasive bladder cancer at 48 and 96 weeks.
- Cretostimogene has FDA Fast Track and Breakthrough Therapy designations; BOND-003 enrolled 112 patients globally.
Financial Impact
No financial figures provided in the press release; CG Oncology is a late-stage clinical biopharmaceutical company with no approved products or disclosed revenue.
Risk Factors
- FDA may still issue a Complete Response Letter (CRL) on safety/efficacy or CMC grounds, which would be severely negative for a single-asset biotech.
- Competing bladder-sparing therapies (e.g., intravesical gemcitabine-docetaxel, pembrolizumab) may limit commercial uptake even if approved.
- Forward-looking statements caution that interim results are not necessarily indicative of final outcomes; regulatory review timelines are uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3333936 |
Track record
25 reports on CGON
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
- Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
- Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
- Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
- Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
- Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
- Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers